68 listed sites: Canada (8); China (5); France (6); Italy (5); Japan (5); Mexico (4); Poland (8); Spain (6); United States (21) - 04 Sep `26Zasocitinib tablets for nonsegmental vitiligo

Zasocitinib tablets for nonsegmental vitiligo

Official title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants With Nonsegmental Vitiligo

Status: Recruiting now

Description:

Takeda plans to enroll about 200 participants. The study drug is an experimental oral or topical immune-modulating medicine designed to reduce inflammatory signaling. Researchers hope it will slow melanocyte damage and help skin regain color. Possible effects may include headache, stomach upset, skin irritation, and infections; the full safety profile is still being studied. People ages 18 to 75 may qualify. The study is recruiting at 70 listed sites across 9 countries.

Start date: November 03, 2025

Completion date: November 09, 2027

Organizer: Takeda

Contact: Takeda Contact

Tel.: +1-877-825-3327

Email: medinfoUS@takeda.com

Link: https://clinicaltrials.gov/study/NCT07108283

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Zasocitinib tablets for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions

  • Is there a traditional medicine to treat vitiligo?

    Traditional remedies can be helpful for managing stress or general metabolic health, but when it comes to vitiligo, the evidence is limited. While some natural supplements provi...

  • Can chemicals cause vitiligo?

    Certain chemicals can trigger vitiligo, leading to a condition known as chemical-induced vitiligo. While clinically and histologically indistinguishable from other types of viti...

  • Can Ayurveda help with vitiligo?

    Ayurveda, the ancient Indian system of holistic medicine, focuses on balancing body energies (Doshas) and improving digestion. While it offers a valuable perspective on "whole-b...